Issued on behalf of Avant Technologies Inc.
VANCOUVER – Baystreet.ca News Commentary – Later this week in Geneva, Switzerland, the World Health Organization (WHO) will be hosting a workshop session titled “Enabling AI for Health Innovation and Access." As the AI revolution sweeps its way across the health industry, its benefits are being recognized as it can help ease the strain on health care services. Recently, the U.S. Department of Justice (DOJ) credited AI tools with a recent historic healthcare fraud crackdown. Now AI tools are outperforming medical doctors in diagnosing complex medical cases, marking a major milestone in the revolution. Now there are plenty of opportunities for retail investors to get more involved in the AI overhaul of healthcare, by paying more attention to innovators making headlines, including Avant Technologies, Inc. (OTCQB: AVAI), Healthcare Triangle, Inc. (NASDAQ: HCTI), Palantir Technologies Inc. (NASDAQ: PLTR), OmniAb, Inc. (NASDAQ: OABI), and Tempus AI, Inc. (NASDAQ: TEM).
The global AI in healthcare market is expected to surge past $110 billion by 2030, growing at an annual rate of 38.6%, according to MarketsandMarkets. By 2035, Accenture projects AI could add another $461 billion in value to a healthcare sector already on track to surpass $2.26 trillion. Together, these forecasts highlight how AI is rapidly transforming clinical workflows, back-end systems, and the financial architecture of modern medicine.
Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech set to reach a key regulatory milestone today, July 7, with their pre-submission meeting with the U.S. FDA. The session will help define the clinical roadmap for Vision AI, their flagship disease-screening platform, as the team moves toward 510(k) clearance for commercial use in the U.S. market. With support from global CRO Fortrea and seasoned regulatory advisors, the companies are focused on streamlining the approval process and paving the way for large-scale diabetic screening nationwide.
“We’re approaching a key milestone,” said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova’s technology portfolio. “We’ve been preparing thoroughly with the support of an experienced CRO and expert regulatory advisors, and we’re optimistic about the outcome. Diabetic retinopathy is the number one cause of preventable blindness worldwide. That’s unacceptable—and we believe technology can change that. But this is just the beginning. Retinal screening offers a gateway to detecting many systemic conditions early—like Alzheimer’s, cardiovascular disease, and more.”
Avant’s broader diabetes push is now entering a critical phase. It has signaled intentions to launch a standalone company to develop a potential treatment for diabetes, complementing its screening and detection suite. This would streamline its structure by integrating data, IP, and leadership under one roof, eliminating the holding-company inefficiencies currently in place.
Over 30% of those living with diabetes will develop diabetic retinopathy, a disease that can be prevented with an accurate diagnosis. More recently, Avant and joint-venture partner Ainnova Tech have begun offering free Vision AI scans inside Grupo Dökka’s Fischel and La Bomba pharmacy chains.
Avant’s Vision AI platform uses retinal imaging and artificial intelligence to rapidly detect diabetic retinopathy and other retinal diseases, as well as systemic conditions like fatty liver, chronic kidney disease, and cardiovascular risk.
The team is finalizing a low-cost, cloud-connected retinal camera that could operate in clinics and rural settings without specialist staff. And with new disease modules in the pipeline—including a blood test-linked dementia screening tool—Avant is steadily building out a scalable, multi-condition platform designed to close the loop between early detection and timely intervention.
“We’re committed to pushing the boundaries of preventive care, improving both life expectancy and quality of life for people around the world,” added Vargas. “That’s the mission behind everything we do.”
Recently, Avant signed a non-binding letter of intent to acquire 100% of Ainnova Tech—bringing leadership, data, and intellectual property together ahead of a scheduled FDA pre-submission meeting in July. Folding the joint venture into a single public entity would remove the current holding-company structure, streamlining everything from regulatory filings to revenue recognition.
CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
Healthcare Triangle, Inc. (NASDAQ: HCTI) has launched a strategic cost optimization plan targeting $1.8 million in annual savings. The initiative will consolidate functions, apply AI-based efficiencies, and shift focus toward high-growth segments.
"This plan reflects a disciplined approach to capital allocation as we enter a new phase of growth," said Sujatha Ramesh, Chief Operating Officer, and David Ayanoglou, Chief Financial Officer of HCTI. "We are confident that this initiative will drive greater efficiency, improve shareholder value, and enable sustained innovation for our clients."
Management expects these actions to strengthen the company’s financial foundation while supporting continued innovation in digital healthcare.
Palantir Technologies Inc. (NASDAQ: PLTR) is teaming up with TeleTracking to transform healthcare operations using AI. Executives from both companies say the collaboration marks a new era in healthcare efficiency driven by AI-native infrastructure.
"This partnership with TeleTracking represents the AI revolution in healthcare we are in the midst of-where we continue to move closer to a world where all hospitals and health systems are embracing, implementing and operating with an AI-powered approach, helping to streamline operations allowing for increased focus on providing the best level of care," said Alex Karp, CEO at Palantir.
The combined platform brings real-time insights, predictive analytics, and intelligent automation to hospitals looking to optimize staffing, capacity, and patient flow.
OmniAb, Inc. (NASDAQ: OABI) recently showcased its AI-powered xPloration® platform at the PEGS Boston Summit, emphasizing its ability to screen millions of B-cells and generate diverse antibody libraries in hours.
"Thorough mining of primary B-cells from immunized animals presents a major challenge in therapeutic antibody discovery," said Dr. Bob Chen, Ph.D., Vice President, Discovery Systems. “Traditional methods often restrict antibody diversity and require weeks to complete. In contrast, the xPloration platform processes millions of single B-cells and recovers thousands of antibody variants within hours, achieving impactful results. By enabling deep mining of immunized repertoires with flexible assays, xPloration excels at rare hit selection, large repertoire analysis, and screening for various targets including membrane proteins. It is an integral part of our discovery engine, and our validated workflow for all OmniAb animals ensures precision and efficiency in partner discovery projects."
The system enhances therapeutic discovery by combining fast cell recovery with image-based selection, improving accuracy and speed. OmniAb also introduced a Partner Access Program to expand use of the platform among its collaborators.
Tempus AI, Inc. (NASDAQ: TEM) subsidiary Ambry Genetics has published a peer-reviewed study confirming the 99.5% accuracy of its CARE Program®, a digital tool for assessing hereditary cancer risk. The software automates the interpretation of complex NCCN Guidelines®, helping clinicians identify high-risk patients for genetic testing with speed and precision. CARE integrates with electronic health records, collects patient history, and delivers real-time, guideline-aligned assessments—all through a HIPAA-compliant platform. With proven clinical utility, the system is now positioned to scale across health systems seeking personalized, proactive cancer care.
Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
Baystreet.ca
[email protected]
(250) 999-4849
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
